drugset / Trial / NCT06535412
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2028-12-17
- Completion
- 2028-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMC-002 | Unknown | 0.8 mg/kg | Intravenous |
| Subject | IMC-002 | Unknown | 1.2 mg/kg | Intravenous |
| Subject | IMC-002 | Unknown | 1.6 mg/kg | Intravenous |
| Subject | IMM0306S | Unknown | 2 mg/kg | Subcutaneous |
| Subject | IMM0306S | Unknown | 4 mg/kg | Subcutaneous |
| Subject | IMM0306S | Unknown | 6 mg/kg | Subcutaneous |